Scientists squeeze and release heart failure patients to uncover exercise secrets
NCT ID NCT05764564
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how applying positive or negative pressure around the body affects exercise in people with heart failure with preserved ejection fraction. 27 participants, including healthy volunteers and heart failure patients, were tested non-invasively and some invasively. The goal was to measure changes in cardiac output, heart rate, and other factors during exercise.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand how body pressure changes affect exercise capacity in heart failure patients, potentially guiding future treatments.
- What could go wrong
- This is a small, early-phase study (27 participants) focused on understanding mechanisms, not testing a treatment. Results may not apply to all heart failure patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE, DIASTOLIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single gene infusion rebuild failing hearts?
- Can special exercise programs help heart failure patients breathe easier?
- Gut health breakthrough? probiotic shows promise for heart failure
- Could mounjaro ease heart failure in obesity? new trial investigates
- New heart failure drug enters first human safety trial
- Heart shunt device put to the test in 750-Patient Sham-Controlled trial